Naltrexone–bupropion for managing overweight and obesity

  • Technology appraisal guidance
  • TA494
  • Published: 

Review decision – January 2020

Decision to move the existing TA494 guidance to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA494; Naltrexone-bupropion (prolonged release) for managing overweight and obesity.

There is no new evidence that would lead to a change in the existing recommendations. TA494 will move to the static list and the forthcoming update of CG189 (Obesity: identification, assessment and management) will cross-refer to the recommendations.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

Proposal paper 

Stakeholder list 

This page was last updated: